FDA Makes Broad Concessions In Settling Pacira Promotion Suit

In a resounding victory for Pacira Pharmaceuticals Inc., FDA has agreed to formally withdraw its warning letter objecting to the promotion of Exparel (bupivacaine liposome injectable suspension) and to approve a labeling supplement specifying that the post-surgical pain treatment is not limited to any specific surgery or site.